AtheroGenics to Discontinue AGIX-4207 Pharmaceutical company AtheroGenics Inc. said Wednesday that a mid-stage trial to evaluate its AGIX-4207 treatment for rheumatoid arthritis failed to meet the study #39;s endpoint, showing no significant improvement compared with placebo.